Updates in Medicine articles by specialty
Cardiology
17 articles · Newest first
Antiplatelet Management in Coronary Syndromes: 2026 AHA Scientific Statement
Individualising antiplatelet selection, duration and de-escalation to balance thrombotic protection against bleeding risk.
2026 ADA/EASD Type 2 Diabetes Management Update: From Glucose Control to Early Organ Protection
A practical guide to the 2026 consensus: consider organ-protective treatment early, then individualise care around cardiovascular and kidney risk, weight and glycaemic goals.
Nutrition to Prevent and Treat Heart Disease in 2026
Putting the 2026 ACC Scientific Statement into practice: focus on food quality, healthy substitutions and sustainable dietary patterns.
LDL-C Management in 2026: A Practical Guide to Risk-Based Targets and Treatment
Assess ASCVD risk, set an appropriate LDL-C goal, intensify treatment when needed and sustain LDL-C lowering over time.
Lipoprotein(a) in Practice: Who to Test, How to Interpret It, and What to Do When It Is High
A practical approach to universal Lp(a) measurement, cardiovascular risk interpretation and management based on the 2026 National Lipid Association Lipid Simplified review.
Diuretics in acute heart failure with rising creatinine: continue, reduce or stop?
How to distinguish a creatinine rise during effective decongestion from one that requires a change in treatment.
Atenolol Outperformed Bisoprolol After MI Without Recorded Heart Failure
A French observational study found fewer major cardiovascular events with atenolol over two years—but no statistically significant mortality difference.
The 2026 ESC Heart Failure Guideline: From Diagnosis to Advanced Heart Failure
A practical guide to classification, diagnosis, foundational therapy, decompensated HF, devices, comorbidities, advanced HF and follow-up.
Infective endocarditis in 2026: putting the AHA scientific statement into practice
A practical approach to diagnosis, multimodality imaging, antimicrobial treatment, surgical timing and post-operative care.
Heart Failure Classification in 2026: How the ESC Guidelines and Second Universal Definition Fit Together
Understanding stages, ejection-fraction phenotypes and changing disease trajectories without forcing false equivalence.
Pulmonary Embolism in 2026: A Practical Approach to Diagnosis, Risk Stratification and Management
From clinical suspicion and D-dimer testing to the new AHA/ACC PE categories, anticoagulation, reperfusion therapy and follow-up.
Single-Infusion PCSK9 Base Editing Produces Substantial LDL-C Lowering Sustained Beyond One Year
Phase 1 data suggest that one-time in-vivo PCSK9 editing can produce large and durable LDL-C reductions, although long-term safety and cardiovascular benefit remain uncertain.
The 2026 ESC Guideline on Cardiovascular Disease and Chronic Kidney Disease
A practical approach to managing chronic kidney disease and cardiovascular disease together.
Met-HeFT 2026: Metformin Failed to Reduce Cardiovascular Events in HFrEF
The randomised trial tested whether metformin provides cardiovascular protection beyond glucose lowering in HFrEF.
The 2026 ESC Cardiogenic Shock Definition
A pathophysiology-based definition centred on three essential diagnostic pillars.
What’s new in valvular heart disease?
Earlier intervention, better phenotyping and lifetime planning are reshaping aortic, mitral and tricuspid valve care.
Fifth Universal Definition of Myocardial Infarction 2026: What Clinicians Need to Know
A mechanism-based framework for distinguishing myocardial infarction from myocardial injury and identifying its cause.